HPTX Share Price

Open 45.98 Change Price %
High 46.02 1 Day 0.02 0.04
Low 45.98 1 Week 0.00 0.00
Close 45.99 1 Month 0.00 0.00
Volume 308104 1 Year 0.00 0.00
52 Week High 3.64
52 Week Low 1.65
HPTX Important Levels
Resistance 2 46.03
Resistance 1 46.01
Pivot 46.00
Support 1 45.97
Support 2 45.95
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Hyperion Therapeutics, Inc. (NASDAQ: HPTX)

HPTX Technical Analysis 5
As on 7th May 2015 HPTX Share Price closed @ 45.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 28.02 & Strong Buy for SHORT-TERM with Stoploss of 39.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
HPTX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
HPTX Other Details
Segment EQ
Market Capital 178032608.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.hyperiontx.com
HPTX Address
HPTX
2000 Sierra Point Parkway
Suite 400
Brisbane, CA 94005
United States
Phone: 650-745-7802
Fax: 650-871-7029
Interactive Technical Analysis Chart Hyperion Therapeutics, Inc. ( HPTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hyperion Therapeutics, Inc.
HPTX Business Profile
Hyperion Therapeutics, Inc. (Hyperion)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company develops Ravicti (glycerol phenylbutyrate) to treat the prevalent urea cycle disorders (UCD) and hepatic encephalopathy (HE). On December 23, 2011, the Company submitted a new drug application (NDA) for Ravicti for the chronic management of UCD in patients aged six years and above based on data from its pivotal Phase III trial in adult patients and the results of two Phase II trials, one in adults and one in pediatric patients aged 6 through 17 years. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.